Evidence map›Paper›PMID 23989717›Full record

ReviewCirculation research2013

Emerging paradigms in cardiomyopathies associated with cancer therapies.

Bonnie Ky, Pimprapa Vejpongsa, Edward T H Yeh, Thomas Force, Javid J Moslehi

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Circulation research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 3 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 3 syntheses or guidelines pooled it, 167 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Artificial intelligence: Applications in cardio-oncology and potential impact on racial disparities.American heart journal plus : cardiology research and practice · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. The Hippo Signaling Pathway as a Drug Target in Familial Dilated Cardiomyopathy.International journal of drug discovery and pharmacology · 2022
    Article
  17. Article
  18. Review
  19. Review
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Bonnie KyDivision of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Pimprapa Vejpongsa
Edward T H Yeh
Thomas Force
Javid J Moslehi
Temple University · USUniversity of Pennsylvania · US

Funding

Targeted Cancer Therapeutics and Heart Failure: Mechanisms and Post-injury RepairP01HL091799 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI KOCH, WALTER J. · 2008 to 2018
$23.1M
SIGNALING MECHANISMS GOVERNING CARDIAC HYPERTROPHYR01HL061688 · NHLBI · VANDERBILT UNIVERSITY · PI FORCE, THOMAS · 1999 to 2014
$5.7M
TNNI3K: A cardiac-specific kinase regulating ischemic injury and fibrotic remodelR01HL114124 · NHLBI · VANDERBILT UNIVERSITY · PI LAL, HIND · 2012 to 2015
$1.5M
The Role of Neuregulin in Human Cardiac Remodeling and Heart FailureK23HL095661 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KY, BONNIE · 2010 to 2014
$704k
NHLBI NIH HHS K23 HL095661NHLBI NIH HHS P01 HL091799NHLBI NIH HHS R01 HL061688NHLBI NIH HHS R01 HL114124
6 · The paper itself

Abstract

The cardiovascular care of cancer patients (cardio-oncology) has emerged as a new discipline in clinical medicine, given recent advances in cancer therapy, and is driven by the cardiovascular complications that occur as a direct result of cancer therapy. Traditional therapies such as anthracyclines and radiation have been recognized for years to have cardiovascular complications. Less expected were the cardiovascular effects of targeted cancer therapies, which were initially thought to be specific to cancer cells and would spare any adverse effects on the heart. Cancers are typically driven by mutations, translocations, or overexpression of protein kinases. The majority of these mutated kinases are tyrosine kinases, though serine/threonine kinases also play key roles in some malignancies. Several agents were developed to target these kinases, but many more are in development. Major successes have been largely restricted to agents targeting human epidermal growth factor receptor-2 (mutated or overexpressed in breast cancer), BCR-ABL (chronic myelogenous leukemia and some cases of acute lymphoblastic leukemia), and c-Kit (gastrointestinal stromal tumor). Other agents targeting more complex malignancies, such as advanced solid tumors, have had successes, but have not extended life to the degree seen with chronic myelogenous leukemia. Years before the first targeted therapy, Judah Folkman correctly proposed that to address solid tumors one had to target the inherent neoangiogenesis. Unfortunately, emerging evidence confirms that angiogenesis inhibitors cause cardiac complications, including hypertension, thrombosis, and heart failure. And therein lies the catch-22. Nevertheless, cardio-oncology has the potential to be transformative as the human cardiomyopathies that arise from targeted therapies can provide insights into the normal function of the heart.

Indexed as

Angiogenesis InhibitorsAnimalsAnthracyclinesCardiomyopathiesCardiotoxinsHumansAngiogenesis InhibitorsAnthracyclinesCardiotoxinsangiogenesis inhibitorsanthracyclinescancercardiomyopathycardio-oncologychemotherapiesHER2-targeted therapies

Identifiers

PMID23989717
PMCPMC4046703
OpenAlexW2136889865

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.